Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.
|Published (Last):||9 August 2004|
|PDF File Size:||6.37 Mb|
|ePub File Size:||12.64 Mb|
|Price:||Free* [*Free Regsitration Required]|
Please do try to use an alternate pdf reader in case the file is unopenable with adobe. The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.
Clicking on the download link will add the report to your downloaded reports.
Quick Links for ranbaxylaboratories. Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated 20110-11 statements of the Company, and therefore, no separate disclosure on segment information is given in these fnancial statements. Please do reach out to us annuql contactus reportjunction. 20010-11 liabilities and commitments to the extent not provided for As at As at 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on anual of subsidiaries, to the extent of limits 6, As per the Scheme, the share exchange ratio has been proposed as 0.
The Company will issue shares to the Trust which will allocate the shares to the respective employees upon exercise of stock options from time to time under ESOP – Options are granted at the discretion of the committee to selected employees depending upon certain criterion.
Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. Pursuant to the transaction, the Company has recorded a gain of Rs. The Company received the fnal assessment order from the AO in November whereby demand of Rs The options vests evenly over a period of three years from the date of grant. The amount above represents the difference payable. Abnual amount recognised in the Statement of Proft and Loss represents consequential cost sales return, inventory write off and customer claim recognised by the Company.
The Company has not accepted the same and has fled its objections before the DRP. It is the largest exporter of bulk drugs and pharmaceutical dosag. The sales consideration of Rs. Description cannot exceed characters. Options lapse, if they are not exercised prior to the expiry date, which is three months from the date of the vesting.
Annual Reports & Presentations
This scheme limits the maximum grant of options to an employee or a director at 30, in any given year. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol. ESOS provides that the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are 2100-11, prior to the date of the meeting of the Committee in which the options are granted.
The Company is fully cooperating with this information request and is in dialogue with the US DOJ for submission of the requisite information.
The Company is in dialogue with these regulatory agencies and is addressing their concerns. These derivatives are not used for trading or speculation purposes.
Your Account is not yet activated Click here to receive activation mail once again. Further, the Company has deposited Rs. ESOS I and II provide that the grant price of options is to be determined at the average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant. It also includes a demand of Rs. The following are the outstanding derivative contracts entered into by the Company: Daiichi Sankyo Propharma Co.
In calculating these provisions, the management has used the best information and estimates, presently available.
Nifty bounces over ; Og languishes 17 Feb 10 Commitments i Estimated amount of contracts remaining to be executed on capital account and not Pending disposal of the arnbaxy, the management considers the impact as unascertainable. Foreign funds hint at hiking India allocation 25 Mar 10 Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance forward contractsoptions, currency swaps, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.
The Company expects to resume API bulk shipments to EU countries from Toansa manufacturing facility upon receipt of clearances from relevant regulatory authorities.
Annual Reports & Presentations | Sun Pharmaceutical Industries Ltd.
Click here to change registered Email ID. You will be able to download it at any time during the subscription period. As at 31 Ganbaxythere are no such derivative contracts which are classifed as cash fow hedges. Ranbaxy Laboratories is not traded in the last 30 days.
RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents. Dion Global Solutions Limited. Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 A, Italy Ranbaxy Malaysia Sdn. However, considering the above matters relating to the Toansa manufacturing facility, provisions primarily relating to inventories, trade commitments, sales return etc.
The amount is excluding interest and penalty, if any. The options vests evenly over a period of fve years from the date of grant.